Quantification of risk factors for herpes zoster: population based case-control study
- PMID: 25134101
- PMCID: PMC4019782
- DOI: 10.1136/bmj.g2911
Quantification of risk factors for herpes zoster: population based case-control study
Abstract
Objectives: To quantify the effects of possible risk factors for herpes zoster at different ages.
Design: Case-control study.
Setting: UK Clinical Practice Research Datalink primary care data.
Participants: 144 959 adults diagnosed with zoster between 2000 and 2011; 549,336 age, sex, and practice matched controls.
Main outcome measures: Conditional logistic regression was used to generate adjusted odds ratios to estimate the strength of association of each potential risk factor with zoster and assess effect modification by age.
Results: The median age of the cases and controls was 62 years. Factors associated with increased risk of zoster included rheumatoid arthritis (3111 (2.1%) v 8029 (1.5%); adjusted odds ratio 1.46, 99% confidence interval 1.38 to 1.55), inflammatory bowel disease (1851 (1.3%) v 5118 (0.9%); 1.36, 1.26 to 1.46), chronic obstructive pulmonary disease (6815 (4.7%) v 20 201 (3.7%); 1.32, 1.27 to 1.37), asthma (10 243 (7.1%) v 31 865 (5.8%); 1.21, 1.17 to 1.25), chronic kidney disease (8724 (6.0%) v 29 437 (5.4%); 1.14, 1.09 to 1.18), and depression (6830 (4.7%) v 22 052 (4.0%); 1.15, 1.10 to 1.20). Type 1, but not type 2, diabetes showed some association with zoster (adjusted odds ratio 1.27, 1.07 to 1.50). The relative effects of many assessed risk factors were larger in younger patients. Patients with severely immunosuppressive conditions were at greatest risk of zoster-for example, patients with lymphoma (adjusted odds ratio 3.90, 3.21 to 4.74) and myeloma (2.16, 1.84 to 2.53), who are not eligible for zoster vaccination.
Conclusions: A range of conditions were associated with increased risk of zoster. In general, the increased risk was proportionally greater in younger age groups. Current vaccines are contraindicated in people at the greatest risk of zoster, highlighting the need for alternative risk reduction strategies in these groups.
© Forbes et al 2014.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at
Similar articles
-
The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.Arthritis Res Ther. 2011;13(5):R174. doi: 10.1186/ar3497. Epub 2011 Oct 24. Arthritis Res Ther. 2011. PMID: 22024532 Free PMC article.
-
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099. JAMA. 2013. PMID: 23462785 Free PMC article.
-
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.Arthritis Rheumatol. 2016 Sep;68(9):2328-37. doi: 10.1002/art.39670. Arthritis Rheumatol. 2016. PMID: 26990731 Free PMC article.
-
Incidence and Prevention of Herpes Zoster Reactivation in Patients with Autoimmune Diseases.Rheum Dis Clin North Am. 2017 Feb;43(1):111-121. doi: 10.1016/j.rdc.2016.09.010. Epub 2016 Oct 22. Rheum Dis Clin North Am. 2017. PMID: 27890168 Review.
-
Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis.Mayo Clin Proc. 2017 Dec;92(12):1806-1821. doi: 10.1016/j.mayocp.2017.10.009. Mayo Clin Proc. 2017. PMID: 29202939 Review.
Cited by
-
The relationship between Zoster serology, vaccination uptake and infection rates: a single-centre cross-sectional study.Rheumatol Adv Pract. 2024 Oct 8;8(4):rkae127. doi: 10.1093/rap/rkae127. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 39469493 Free PMC article.
-
Burden of Herpes Zoster in Individuals With Chronic Conditions in the Republic of Korea: A Nationwide Population-Based Database Study.Open Forum Infect Dis. 2024 Sep 18;11(10):ofae535. doi: 10.1093/ofid/ofae535. eCollection 2024 Oct. Open Forum Infect Dis. 2024. PMID: 39355262 Free PMC article.
-
Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine.Biomolecules. 2024 Jun 22;14(7):739. doi: 10.3390/biom14070739. Biomolecules. 2024. PMID: 39062454 Free PMC article. Review.
-
Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.Eur Respir J. 2024 Aug 8;64(2):2400462. doi: 10.1183/13993003.00462-2024. Print 2024 Aug. Eur Respir J. 2024. PMID: 38901886 Free PMC article. Review.
-
Rare case of postherpetic abdominal pseudohernia in a patient on peritoneal dialysis.J Nephrol. 2024 Sep;37(7):2017-2019. doi: 10.1007/s40620-024-01954-3. Epub 2024 Jun 5. J Nephrol. 2024. PMID: 38837002 Free PMC article.
References
-
- Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26-33. - PubMed
-
- Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002;347:340-6. - PubMed
-
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84. - PubMed
-
- Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454-67. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical